Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
Research output: Contribution to journal › Journal article › peer-review
Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.
Original language | English |
---|---|
Journal | Lancet |
Volume | 381 |
Issue number | 9881 |
Pages (from-to) | 1905-15 |
Number of pages | 11 |
ISSN | 0140-6736 |
DOIs | |
Publication status | Published - 1 Jun 2013 |
- Adolescent, Adult, Analysis of Variance, Antibodies, Monoclonal, C-Peptide, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Immunologic Factors, Insulin-Secreting Cells, Interleukin 1 Receptor Antagonist Protein, Interleukin-1, Male, Treatment Outcome, Young Adult
Research areas
ID: 96512501